Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct:66:123-128.
doi: 10.1016/j.coi.2020.10.002. Epub 2020 Nov 4.

Mechanisms of non-type 2 asthma

Stephanie N Hudey  1 , Dennis K Ledford  1 , Juan Carlos Cardet  2
Affiliations
Review

Mechanisms of non-type 2 asthma

Stephanie N Hudey et al. Curr Opin Immunol. 2020 Oct.

Abstract

Non-type 2 inflammation (Non-T2)-mediated asthma is difficult to define due to lack of signature biomarkers. It exists in the absence of T2-high or eosinophilic inflammation and includes neutrophilic and paucigranulocytic subtypes. Several cell types and cytokines, including Th1, Th17, IL-6, and IL-17, contribute to mechanisms of non-T2 asthma. Neutrophil extracellular traps (NETs) and inflammasome activation likely play a role in severe neutrophilic asthma. Several mechanisms lead to uncoupling of airway hyperresponsiveness and remodeling from airway inflammation in paucigranulocytic asthma. Recent research on transcriptomics and proteomics in non-T2 asthma is discussed in this review. Investigations of specific drug therapies for non-T2 asthma have been disappointing, and remain an important area for future clinical studies.

PubMed Disclaimer

Conflict of interest statement

JCC and SH have nothing to disclose.

References

    1. Hastie AT, Mauger DT, Denlinger LC, Coverstone A, Castro M, Erzurum S, Jarjour N, Levy BD, Meyers DA, Moore WC et al.: Baseline sputum eosinophil + neutrophil subgroups’ clinical characteristics and longitudinal trajectories for NHLBI Severe Asthma Research Program (SARP 3) cohort. J Allergy Clin Immunol 2020, 146:222–226. - PMC - PubMed
    1. Schleich FN, Zanella D, Stefanuto PH, Bessonov K, Smolinska A, Dallinga JW, Henket M, Paulus V, Guissard F, Graff S et al.: Exhaled volatile organic compounds are able to discriminate between neutrophilic and eosinophilic asthma. Am J Respir Crit Care Med 2019, 200:444–453. - PubMed
    1. Ray A, Kolls JK: Neutrophilic inflammation in asthma and association with disease severity. Trends Immunol 2017, 38:942–954. - PMC - PubMed
    1. Ricciardolo FLM, Sorbello V, Folino A, Gallo F, Massaglia GM, Favata G, Conticello S, Vallese D, Gani F, Malerba M et al.: Identification of IL-17F/frequent exacerbator endotype in asthma. J Allergy Clin Immunol 2017, 140:395–406. - PubMed
    1. Vroman H, Bergen IM, van Hulst JAC, van Nimwegen M, van Uden D, Schuijs MJ, Pillai SY, van Loo G, Hammad H, Lambrecht BN et al.: TNF-alpha-induced protein 3 levels in lung dendritic cells instruct TH2 or TH17 cell differentiation in eosinophilic or neutrophilic asthma. J Allergy Clin Immunol 2018, 141:1620–1633 e1612. - PubMed

Publication types